Key clinical point: Bendamustine plus rituximab (BR) appears to be an effective induction regimen for patients with mantle cell lymphoma, regardless of whether they are transplant eligible or ineligible.
Major finding: In total, there was an 87% overall response rate among patients treated with BR, with more than half of patients achieving a complete response. In the subset of patients who underwent autologous stem cell transplant, outcomes after transplant were not significantly different for patients treated with BR versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Study details: A population-based analysis of 190 patients with MCL who were treated with BR, compared with 140 patients in a historical cohort treated with R-CHOP.
Disclosures: Dr. Villa reported financial disclosures related to Roche, Abbvie, Celgene, Seattle Genetics, and other companies.
Villa D et al. ASH 2019, Abstract 2814.